Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.02

€1.02

0.790%
0.008
0.790%
-
 
28.03.24 / Tradegate WKN: A1H65A / Symbol: PHGUF / Name: Pharming Group / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Pharming Group Stock

The Pharming Group stock is trending slightly upwards today, with an increase of €0.008 (0.790%) compared to yesterday's price.

Pros and Cons of Pharming Group in the next few years

Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pharming Group vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pharming Group 0.790% -1.727% -2.010% -13.440% -1.254% -5.709% 30.779%
ProQR Therapeutics N.V. -0.470% -7.781% 7.971% -36.711% 16.536% -70.620% -
Ardelyx Inc. -1.160% -6.371% -22.654% 73.980% 16.955% 25.791% -
Salarius Pharmaceuticals Inc. 2.420% -18.824% -22.617% -76.389% -25.405% -98.665% -99.992%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-06

Diving into the financials of Pharming Group, a US-listed company in the Biotechnology & Medical Research industry, an initial scan reveals a business with considerable liquidity, as evidenced by a healthy cash balance in recent years. Although the innovativeness of the sector can often lead to volatile financials, Pharming Group shows some stability in their operational performance, with growing total assets year-on-year and a robust gross profit.

Increasing Total Assets: The balance sheet illustrates year-over-year growth in total assets from $340.8 million in 2020 to $425.8 million in 2022. Such an uptrend is indicative of an expanding business with potential scaling capabilities.

Healthy Cash Position: With cash reserves of $207.3 million as of the end of 2022, Pharming Group demonstrates strong liquidity. The ability to maintain a solid cash buffer is crucial for research-intensive sectors, which the company seems to be managing well.